Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Mylan has launched a generic version of Biogen's Tecfidera (dimethyl fumarate), a drug for treating relapsing multiple sclerosis (MS). Tecfidera is Biogen’s top-selling drug with 2019 global sales of $4.4 billion. Mylan is launching dimethyl...

Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Cambridge, Massachusetts-based company developing biosimilars and new biologics for rare immune-mediated diseases, for $6.5 billion. Momenta’s lead asset is...

Bristol Myers Squibb (BMS) and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have formed a collaboration, worth up to $475 million, for Dragonfly’s immunotherapy candidate, DF6002, for...

Eisai's US subsidiary, Eisai Inc., has announced plans to re-locate its US headquarters in Woodcliff Lake, New Jersey to the former Roche headquarters campus in Nutley, New Jersey. The move is expected to be completed in late 2021 and will transfer...

Bayer has agreed to acquire KaNDy Therapeutics, a Stevenage, UK-based clinical-stage biopharmaceutical company, to expand its drug-development pipeline in women’s healthcare, in a deal worth up to $875 million. KaNDy Therapeutics recently...

A roundup of news from Germany (Evotec, Secarna Pharmaceuticals, CureVac), Japan (Teva, Takeda), and the US (Astellas, Sorrento Therapeutics, and SRI Biosciences). Germany Evotec, Secarna Pharmaceuticals in Pact for Antisense...